A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma-Reference-Cited by-同舟云学术

A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma

Published:2018-01-23 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Oh Eonju,Hong JinWoo,Kwon Oh-Joon,Yun Chae-Ok

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-19300-6.pdf

Reference71 articles.

1. Juratli, T. A., Schackert, G. & Krex, D. Current status of local therapy in malignant gliomas–a clinical review of three selected approaches. Pharmacol. Ther. 139, 341–358, https://doi.org/10.1016/j.pharmthera.2013.05.003 (2013).

2. Hetschko, H. et al. Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma. J Neurooncol 86, 265–272, https://doi.org/10.1007/s11060-007-9472-6 (2008).

3. Qian, C., Sangro, B. & Prieto, J. New strategies to enhance gene therapy efficiency. Gastroenterology 123, 639–642 (2002).

4. Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R. & Wixon, J. Gene therapy clinical trials worldwide to 2012 - an update. J. Gene Med. 15, 65–77, https://doi.org/10.1002/jgm.2698 (2013).

5. Luo, J. et al. Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene. Clin. Cancer. Res. 14, 2450–2457, https://doi.org/10.1158/1078-0432.CCR-07-4596 (2008).

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas;Current Treatment Options in Oncology;2024-06-19

2. Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy;Nature Protocols;2024-05-20

3. Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer;Frontiers in Immunology;2024-05-15

4. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy;International Journal of Molecular Sciences;2024-01-18

5. Mathematical modeling predicts pathways to successful implementation of combination TRAIL-producing oncolytic virus and PAC-1 to treat granulosa cell tumors of the ovary;Cancer Biology & Therapy;2023-11-27